€0.49
Your prediction
Sangamo Therapeutics Inc. Stock
Pros and Cons of Sangamo Therapeutics Inc. in the next few years
Pros
Cons
Performance of Sangamo Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sangamo Therapeutics Inc. | 4.480% | -0.123% | -6.178% | -58.219% | -15.493% | -94.387% | -94.423% |
Ardelyx Inc. | -3.830% | 19.664% | 14.204% | 98.895% | 30.761% | 36.180% | - |
Evolus Inc | 0.830% | 2.542% | 0.000% | 47.561% | 33.702% | 64.626% | - |
Salarius Pharmaceuticals Inc. | -0.980% | -12.174% | -6.047% | -77.430% | -27.207% | -98.343% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Sangamo Therapeutics, a company in the Biotechnology & Medical Research industry with the US symbol SGMO, has displayed a mixed financial performance over the past few years. The company's financial statements show some strengths and areas of concern. A detailed analysis of Sangamo Therapeutics' financials reveals the following pros and cons:
*Pros: *
Revenue Growth: Sangamo Therapeutics has experienced revenue growth over the last three periods, demonstrating its ability to generate higher sales. This is a positive sign for the company as it shows market demand for its products and services.
Comments
News
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
“Sangamo continues to progress its
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes